Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations

The lecture deals with epidemiology, clinical morphological and genetic characteristics of a rare aggressive neuroendocrine carcinoma of the skin, or Merkel cell carcinoma (MC). We describe the algorithms for the differential diagnosis of these tumors and their treatment approaches, and focus on the...

Full description

Bibliographic Details
Main Authors: L. E. Gurevich, E. E. Grishina
Format: Article
Language:Russian
Published: MONIKI 2020-07-01
Series:Alʹmanah Kliničeskoj Mediciny
Subjects:
Online Access:https://www.almclinmed.ru/jour/article/view/1257
id doaj-7b61c9cf4a454de88cc94baded49e4ad
record_format Article
spelling doaj-7b61c9cf4a454de88cc94baded49e4ad2021-07-28T21:11:24ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942020-07-0148212513910.18786/2072-0505-2020-48-014713Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observationsL. E. Gurevich0E. E. Grishina1Moscow Regional Research and Clinical Institute (MONIKI)Moscow Regional Research and Clinical Institute (MONIKI)The lecture deals with epidemiology, clinical morphological and genetic characteristics of a rare aggressive neuroendocrine carcinoma of the skin, or Merkel cell carcinoma (MC). We describe the algorithms for the differential diagnosis of these tumors and their treatment approaches, and focus on the main unresolved issues, such as delayed and erroneous diagnosis, the search for new diagnostic markers and targets for the development of more effective treatment methods. We provide a brief clinical and morphological analysis of 19 own observations of MC in 10 men and 9 women aged 40 to 85 years (57.9% of the patients were above 60 years, 31.6% from 50 to 60 years, and 10.5%, below 50 years). In 42.1% of the cases, the tumors were located in the head, in 15.8% in the limbs, and in 15.8% in the trunk and soft tissues; in the rest of the cases the primary tumor location was not identified. Only in 4 cases MC was diagnosed immediately; in all other cases, the initial diagnoses had been wrong. The diagnosis of MC was established after the analysis of medical files, histological and immunohistochemical biopsy studies and was confirmed by immunohistochemistry. All the tumors were expressing synaptophysin, chromogranin A, CD56; in all cases except one, cytokeratin 20 of the dote-like type, type 2A somatostatin receptors in 66.7%, nuclear survivin in 100%, p53 in 88.9%, CD117 in 57.1%. To illustrate the topic, we present 2 clinical observations of MC. The first case was an 82-year old man who had been living for a long time in the territory with increased sun radiation. A bright red tumor developed on his left upper eyelid, becoming gigantic (5 cm in diameter) within 2 months and bleeding. Despite the radical excision of the tumor, at 2 months after the surgery he developed local recurrence and metastases in regional lymph nodes. Thereafter, he underwent the orbital exenteration and lymphodissection of the affected lymph nodes. The second observation was a 63-year old man. At 10 years after he had had his renal transplant, he developed a mixed skin tumor on the anterior neck surface. The tumor was represented by MC and porocarcinoma with signs of squamous and sebaceous differentiation. These observations demonstrate MC rapid growth, its aggressive potential and such risk factors as prolonged high insolation and long-term drug immunosuppression after organ transplantation. Conclusion: At present, the rarity and low understanding of MC, its rapid growth, late diagnosis, aggressive biological potential and the lack of uniform treatment standards do not allow for cure in most such patients. The solution to the problem lies in the search for the cellular targets that would allow for the development of new effective targeted treatments for these aggressive tumors. In addition, integration of any results obtained in multicenter studies of the disease is essential.https://www.almclinmed.ru/jour/article/view/1257skin tumorsmerkel cell carcinomaclinical coursediagnosisimmunophenotyperelapse
collection DOAJ
language Russian
format Article
sources DOAJ
author L. E. Gurevich
E. E. Grishina
spellingShingle L. E. Gurevich
E. E. Grishina
Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
Alʹmanah Kliničeskoj Mediciny
skin tumors
merkel cell carcinoma
clinical course
diagnosis
immunophenotype
relapse
author_facet L. E. Gurevich
E. E. Grishina
author_sort L. E. Gurevich
title Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
title_short Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
title_full Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
title_fullStr Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
title_full_unstemmed Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
title_sort merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations
publisher MONIKI
series Alʹmanah Kliničeskoj Mediciny
issn 2072-0505
2587-9294
publishDate 2020-07-01
description The lecture deals with epidemiology, clinical morphological and genetic characteristics of a rare aggressive neuroendocrine carcinoma of the skin, or Merkel cell carcinoma (MC). We describe the algorithms for the differential diagnosis of these tumors and their treatment approaches, and focus on the main unresolved issues, such as delayed and erroneous diagnosis, the search for new diagnostic markers and targets for the development of more effective treatment methods. We provide a brief clinical and morphological analysis of 19 own observations of MC in 10 men and 9 women aged 40 to 85 years (57.9% of the patients were above 60 years, 31.6% from 50 to 60 years, and 10.5%, below 50 years). In 42.1% of the cases, the tumors were located in the head, in 15.8% in the limbs, and in 15.8% in the trunk and soft tissues; in the rest of the cases the primary tumor location was not identified. Only in 4 cases MC was diagnosed immediately; in all other cases, the initial diagnoses had been wrong. The diagnosis of MC was established after the analysis of medical files, histological and immunohistochemical biopsy studies and was confirmed by immunohistochemistry. All the tumors were expressing synaptophysin, chromogranin A, CD56; in all cases except one, cytokeratin 20 of the dote-like type, type 2A somatostatin receptors in 66.7%, nuclear survivin in 100%, p53 in 88.9%, CD117 in 57.1%. To illustrate the topic, we present 2 clinical observations of MC. The first case was an 82-year old man who had been living for a long time in the territory with increased sun radiation. A bright red tumor developed on his left upper eyelid, becoming gigantic (5 cm in diameter) within 2 months and bleeding. Despite the radical excision of the tumor, at 2 months after the surgery he developed local recurrence and metastases in regional lymph nodes. Thereafter, he underwent the orbital exenteration and lymphodissection of the affected lymph nodes. The second observation was a 63-year old man. At 10 years after he had had his renal transplant, he developed a mixed skin tumor on the anterior neck surface. The tumor was represented by MC and porocarcinoma with signs of squamous and sebaceous differentiation. These observations demonstrate MC rapid growth, its aggressive potential and such risk factors as prolonged high insolation and long-term drug immunosuppression after organ transplantation. Conclusion: At present, the rarity and low understanding of MC, its rapid growth, late diagnosis, aggressive biological potential and the lack of uniform treatment standards do not allow for cure in most such patients. The solution to the problem lies in the search for the cellular targets that would allow for the development of new effective targeted treatments for these aggressive tumors. In addition, integration of any results obtained in multicenter studies of the disease is essential.
topic skin tumors
merkel cell carcinoma
clinical course
diagnosis
immunophenotype
relapse
url https://www.almclinmed.ru/jour/article/view/1257
work_keys_str_mv AT legurevich merkelcellcarcinomaneuroendocrinecarcinomaoftheskinalecturewithabriefoverviewof19casesanddemonstrationoftwoclinicalobservations
AT eegrishina merkelcellcarcinomaneuroendocrinecarcinomaoftheskinalecturewithabriefoverviewof19casesanddemonstrationoftwoclinicalobservations
_version_ 1721262251443224576